Does oral isotretinoin prevent propionibacterium acnes resistance?

Dermatology

Volumn 195, Issue 1, 1997, Pages 4-9

  Coates, P ^a   Adams, C A ^a   Cunlijfe, W J ^a   Mc Ginley, K T ^b   Eady, E A ^a   Leyden, J J ^b   Ravenscroft, J ^a   Vyakrnam, S ^a   Vowels, B ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acne therapy; Clindamycin; Cutaneous propionibacteria; Erythromycin; Isotretinoin; Oral; Resistance; Tetracycline

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; ERYTHROMYCIN; ISOTRETINOIN; TETRACYCLINE; ZINERYT;

ACNE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIUM ISOLATION; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; RISK BENEFIT ANALYSIS; TOPICAL DRUG ADMINISTRATION; TREATMENT FAILURE; TREATMENT PLANNING;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; MICROBIAL SENSITIVITY TESTS; PILOT PROJECTS; PROPIONIBACTERIUM ACNES;

EID: 0030749908     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246012     Document Type: Article

References (25)

1. Eady EA, Ingham E: Propionibaclerium acnes-Friend or foe? Rev Med Microbiol 1994:5: 163-173.
2. Crawford WW. Crawford IP. Stoughton RB. Cornell RC: Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium allies. J Invest Dermatol 1979;72:187-190.
3. Eady EA. Jones CE, Tipper JL. Cove JH, Cun-liffe WJ. Layton AM: Antibiotic resistant pro-pionibaeteria in acne: Need for policies to modify antibiotic usage. Br Med J 1993:306: 555-556.
4. Forssman T: Antibiotikarcsistenzen beachten. Therapiewoche 1993:43:2248-2252.
5. Marples RR. Kligman AM: Ecological effects of oral antibiotics on the microflora of human skin. Arch Dermatol 1971:103:148-153.
6. Kurokawa I, Nishijinta S. Asada Y: The antibiotic susceptibility of Propionibaclerium acnes: A 15-year bacteriological study and retrospective evaluation. J Dermatol 1988:15: 149-154.
7. Oakley A, Rademaker M. Duftill M. Leng R. Shewan J: Propionibaclerium: Resistance of acne to antibiotics. NZ Med J 1995; 108:43-44.
8. Leyden JJ, McGinley KJ. Cavalieri S. Webster GF, Mills OH. Kligman AM: Propionibaclerium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983:8:41-45.
9. Jones CE, Vyakmam S, Eady EA. Cove JH. Cunliffe WJ: Antibiotic resistant propionibac-teria and acne crisis or conundrum. J Invest Dermatol 1997:108:381.
10. Miller YW, Eady EA, Lacey RW. Cove JH. Jones DN. Cunliffe WJ: Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob C'hemother 1996;38:829-837.
11. Miller YW. Eady EA. Vyakmam S. Jones CE. Cove JH. Cunliffe WJ: One in two close contacts of antibiotics treated acne patients carry resistant propionibacteria on their skin surface. J Invest Dermatol 1997:108:379.
12. Eady EA, Cove JH. Holland KT. Cunliffe WJ: Erythromycin resistant propionibacteria in antibiotic-treated acne patients: Association with therapeutic failure. Br J Dermatol 1989; 121:51-57.
13. Bojar RA. Eady EA, Jones CE, Cunliffe WJ. Holland KT: Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130:329-336.
14. Eady EA. Bojar RA. Jones CE. Cove JH. Holland KT. Cunliffe WJ: The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996:134:107-113.
15. Farmery MR. Jones CE. Eady EA. Cove JH, Cunliffe WJ: In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994:5:63-65.
16. Guin JD. Lummis WL: Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. J Am Acad Dermatol 1982;7:265-268.
17. Gardner KJ. Cunliffe WJ, Eady EA, Cove JH: Variation in comedonal antibiotic concentrations following application of topical tetracycline for acne vulgaris. Br J Dermatol 1994; 131:649-654.
18. Farrell I, Strauss JS. Stranieri AM: The treatment of severe cystic acne with 13-cis-retinoic acid: Evaluation of sebum production and clinical response. J Am Acad Dermatol 1980:3: 602-611.
19. Jones DH. Forster RA. Mitchell J, Cunliffe WJ: Comparison of 13-cis retinoic acid and erythromycin treatment in severe acne. Br J Dermatol 1983:109:27-28.
20. Leyden JJ. McGinley J: Effect of 13-cis retinoic acid on sebum production and Propionibaclerium acnes in severe nodulocystic acne. Arch Dermatol Res 1982:272:331-337.
21. Williamson P, Kligman AM: A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol 1965:45:498-503.
22. Marks R. Dawber RPR: Skin surface biopsy: An improved technique for examination of the horny layer. Br J Dermatol 1971;84:117-123.
23. Layton AM, Hughes BR. MacDonald Hull S. Eady EA, Cunliffe WJ: Scborrhoea-An indicator for poor clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992:17:173-175.
24. Eady EA. Ross JI, Crave JH, Holland KT, Cunliffe WJ: The effects of oral erythromycin therapy for acne on the development of resistance in cutaneous staphylococci and prapioni-bacteria; in Marks R, Plewig G (eds): Acne and Related Disorders. London. Dunitz, 1989, pp 265-270.
25. Ross JI. Eady EA. Cove JH. Jones CE. Ratyal AH, Miller YW, Vyakmam S. Cunliffe WJ: Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA. Antimicrob Agents Chemother 1997;41: 1162-1165.